Pink SheetUS Food and Drug Administration Commissioner Martin Makary is starting to sound like he is very impressed with the agency staff. During an “FDA Direct” podcast timed to mark his first 100 days on th
ScripChinese biotechs are racing to push back the frontiers of combination therapies for antibody-drug conjugates (ADCs), progressing multiple assets into mid-stage clinical development. Beyond the validat
Pink SheetVinay Prasad, director of the US Food and Drug Administration’s Center for Biological Evaluation and Research, defended his recent decisions to overrule reviewers and grant narrower indications to thr
ScripAt least officially, Bristol Myers Squibb and Pfizer’s are selling the anticlotting drug Eliquis (apixaban) directly to consumers to lower costs for patients, especially those who are uninsured, under